JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M203774200 on May 16, 2002

J. Biol. Chem., Vol. 277, Issue 32, 28892-28901, August 9, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/32/28892    most recent
M203774200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuiji, M.
Right arrow Articles by Irimura, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuiji, M.
Right arrow Articles by Irimura, T.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular Cloning and Characterization of a Novel Mouse Macrophage C-type Lectin, mMGL2, Which Has a Distinct Carbohydrate Specificity from mMGL1*

Makoto Tsuiji, Mayuko FujimoriDagger, Yoshimi Ohashi, Nobuaki Higashi, Thandi M. Onami§, Stephen M. Hedrick§, and Tatsuro Irimura

From the Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan and the § Cancer Center and the Division of Biology, University of California, San Diego, La Jolla, California 92093-0687

Received for publication, April 18, 2002, and in revised form, May 16, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A novel mouse macrophage galactose-type C-type lectin 2 (mMGL2) was identified by BLAST analysis of expressed sequence tags. The sequence of mMGL2 is highly homologous to the mMGL, which should now be called mMGL1. The open reading frame of mMGL2 contains a sequence corresponding to a type II transmembrane protein with 332 amino acids having a single extracellular C-type lectin domain. The 3'-untranslated region included long terminal repeats of mouse early transposon. The Mgl2 gene was cloned from a 129/SvJ mouse genomic library and sequenced. The gene spans 7,136 base pairs and consists of 10 exons, which is similar to the genomic organization of mMGL1. The reverse transcriptase-PCR analysis indicates that mMGL2 is expressed in cell lines and normal mouse tissues in a macrophage-restricted manner, also very similar to that of mMGL1. The mMGL2 mRNA was also detected in mMGL1-positive cells, which were sorted from thioglycollate-induced peritoneal cells with a mMGL1-specific monoclonal antibody, LOM-8.7. The soluble recombinant proteins of mMGL2 exhibited carbohydrate specificity for alpha - and beta -GalNAc-conjugated soluble polyacrylamides, whereas mMGL1 preferentially bound Lewis X-conjugated soluble polyacrylamides in solid phase assays. These two lectins may function cooperatively as recognition and endocytic molecules on macrophages and related cells.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Macrophages (MØs)1 and related cells are widely distributed throughout the body, displaying a morphological and functional diversity. They are found in the lymphoid organs, liver, lungs, gastrointestinal tract, central nervous system, serous cavities, bones, synovia, and skin. Resident MØs mediate clearance of senescent or apoptotic cells, produce and secrete cytokines, are involved in hemopoiesis and bone resorption, transport and present antigens, and regulate neuroendocrine processes. Activated MØs are recruited to sites of infection, tissue injury, inflammation, and neoplasia and play crucial roles in tissue repair and pathogenesis (1).

The distribution and functional heterogeneity of MØs derive in part from their specialized plasma membrane receptors (2). Cell surface markers such as F4/80, sialoadhesin, MØ mannose receptor and scavenger receptor type A have significantly contributed to the current understanding of MØ ontogeny and function (3). However, in comparison to other immune cells such as B and T lymphocytes, relatively few MØ-restricted cell surface molecules have been identified. The physiological and pathological roles of these putative markers remain unknown.

Protein-carbohydrate interactions serve a variety of functions in the immune system. A number of lectins (carbohydrate-binding proteins) mediate both pathogen recognition and cell-to-cell interactions using structurally related carbohydrate recognition domains (CRDs). One of the most diversified families of these CRDs is Ca2+-dependent and termed C-type CRDs (4, 5). MØs and related cells such as dendritic cells are known to express several subfamilies of C-type lectins: type 1 multilectins such as MØ mannose receptor and lectins having type II transmembrane configurations such as MØ galactose-type (known previously as galactose/N-acetylgalactosamine-specific) C-type lectin (MGL). These lectins seem to mediate carbohydrate-specific endocytosis (6-11). Little is known regarding the expression of selectins, another subfamily of C-type lectins, in MØs and related cells.

Previously, MGL was cloned from rats, mice, and humans and characterized. The lectin from mice was shown to have specific affinity for highly branched N-linked carbohydrate chains with terminal beta -galactosyl groups and glycopeptides carrying three consecutive alpha -GalNAc-Ser/Thr (Tn-antigens) (12). A human MGL was also shown to have affinity for glycopeptides carrying three consecutive Tn-antigens (13). Surface plasmon resonance revealed that affinity of recombinant hMGL for immobilized glycopeptides increased in parallel with the number of GalNAc residues (14). Tn-antigen was known as a marker of malignant cells, and MGL was shown to play a role as a recognition molecule on MØs for tumor cells (15-17). Immunohistochemical localization of mouse MGL (mMGL) with specific monoclonal antibodies revealed that this lectin has a strong association with MØs residing in connective tissue and those infiltrated into tumor tissues (18-20). Recent studies demonstrated that this lectin is also expressed on the surface of immature dendritic cells and is involved in the uptake of glycosylated antigens in mice and humans (21, 22).

A C-type lectin highly homologous to MGL and expressed mainly on hepatocytes, the hepatic asialoglycoprotein receptor (ASGR), has two isomers in mice, rats, and humans, apparently due to recent gene duplication. Previously, MGL was believed to have a single gene. Southern blotting analysis supported this notion. However, in this report, we describe the properties of another novel MØ galactose-type C-type lectin, mMGL2. As an obvious consequence, the previous mMGL must now be called mMGL1. These lectins are highly homologous to each other except in their cytoplasmic domains and CRDs. We found that mMGL2 has a distinct carbohydrate specificity from mMGL1. These lectins seem to be expressed on the same cells and therefore seem to function cooperatively.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells-- The following cell lines were provided by Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer Tohoku University, Sendai, Japan: L929, JLS-V9, EL4, RLmale 1, YAC-1, BCL1-B20, P815, P388, and M1 cells. RAW264.7 cells were purchased from ATCC. All cells were cultured in RPMI 1640 media with 10% fetal calf serum at 37 °C with 5% CO2.

Thioglycollate-induced peritoneal cells (TG-PEC) were obtained from 6-8-week old female C57BL/6J mice from Clea Japan, Inc (Kawasaki, Japan). These were maintained under pathogen-free conditions. These mice received 1 ml of 4% thioglycollate broth (Difco, Detroit, MI) by intraperitoneal injection. Four days later, mice were sacrificed by neck dislocation, and peritoneal exudate cells were harvested by lavage with 5 ml of RPMI 1640 media on ice.

TG-PEC were suspended in chilled 0.1% BSA/Dulbecco's modified phosphate-buffered saline (DPBS: 137 mM NaCl, 13.4 mM KCl, 40.5 mM Na2HPO4, 7.35 mM KH2PO4, 0.49 mM MgCl2, 0.905 mM CaCl2) containing phycoerythrin-labeled mAb LOM-14 (reactive with mMGL1 and mMGL2 as described below) and biotin-labeled mAb LOM-8.7 (reactive with mMGL1) and then incubated with streptavidin-fluorescein isothiocyanate (Zymed Laboratories Inc., South San Francisco, CA) on ice. The cells were sorted for the expression of mMGL1 (mAb LOM-8.7 staining) by Epics Elite (Beckman Coulter).

Mice-- Mgl1-/- mice were prepared in Hedrick's laboratory at the University of California, San Diego, CA. The details will be published in a separate study (23).

RNA Preparations and RT-PCR Analysis-- Total RNAs were extracted by using Ultraspec RNA zol (Biotecx, Houston, TX) according to the manufacturer's instructions. First-strand cDNA synthesis was carried out using oligo(dT)12-18 and Superscript II (Invitrogen). The cDNA was used as the template in PCR reactions using Ampli Taq Gold polymerase (Applied Biosystems). PCR was performed with specific primers for mMgl1 (5'-TCTCTGAAAGTGGATGTGGAGG-3', 5'-CACTACCCAGCTCAAACACAATCC-3'), mMgl2 (5'-TCTCTGAAAGTGGATGTGGAGG-3', 5'-GCTATAAGTTGTGGGGAGTGGGC-3'), and G3pdh (5'-TGAAGGTCGGTGTGAACGGATTTGGC-3', 5'-CATGTAGGCCATGAGGTCCACCAC-3'). The specific primers were designed with Genetyx-Mac (Software Development Co. Ltd., Tokyo, Japan). The conditions were 94 °C for 30 s, 65 °C for 30 s, and 72 °C for 2 min for 40 cycles. Amplifications of G3pdh were used as a control for cDNA quantity. The conditions were 94 °C for 30 s, 61 °C for 30 s, and 72 °C for 1 min for 25 cycles. The PCR products were then separated on 1% agarose gels, stained with ethidium bromide, and visualized with the Fluor-S image analyzer (Bio-Rad).

Rapid Amplification of cDNA Ends (RACE)-- The poly(A)+ RNA from RAW264.7 cells were isolated using a µMACS mRNA isolation kit (Miltenyi Biotec). Adapter-ligated cDNA were synthesized using the Marathon cDNA amplification kit (CLONTECH). To obtain a full-length cDNA of mMGL2, an antisense primer, AS3 (5'-TCCTCCACATCCACTTTCAGAG-3'), and a sense primer, 3S1 (5'-TTGGAGCGGGAAGAGAAAAACCAG-3'), were designed from the expressed sequence tag clones for 5'-RACE and 3'-RACE reactions, respectively. Reactions were incubated at 95 °C for 10 min followed by 43 cycles at 94 °C for 45 s, 60 °C for 45 s, and 72 °C for 2 min. The resulting 1.5-kbp and 700-bp products were subcloned into the pGEM-T easy vector (Promega UK, Southampton, UK) and sequenced with the dye primer method.

Screening of the Genomic Clone Coded the mMgl2 Gene-- A 129/SvJ mouse genomic library (Stratagene; vector gamma FIXII) was screened with the complete mMGL1 cDNA coding sequence labeled by random priming with 32P by plaque hybridization. The fragments of positive clones were subcloned into pBluescript SK(+) (Stratagene). These clones were sequenced with 24 specific primers with the dye-terminator method. These sequences were assembled and aligned using Genetyx-Mac.

Production and Isolation of Soluble mMGL2-- cDNA encoding mMGL1 and mMGL2 was cloned into pGEM-T easy vector (Promega). The vector was digested with BamHI and SacI (for mMGL1) or BamHI and NotI (for mMGL2). The fragments encoding these neck and CRD domains were separated with agarose gel electrophoresis and inserted into each site of expression plasmid vector pET-21a (Novagen). The BL21(DE3) cells containing the plasmid were grown to mid-log phase at 37 °C in 2× TY medium (1.2 liters) and then treated with isopropyl beta -D-thiogalactoside at a concentration of 1 mM. After isopropyl beta -D-thiogalactopyranoside induction, the cultured cells were washed with 50 mM Tris-HCl, pH 8.0, containing 0.15 M NaCl (TBS) and suspended in TBS containing phenylmethanesulfonyl fluoride. The cell lysates were prepared by freezing and thawing, and after the addition of DNase I (final 50 units/ml) and lysozyme (final 0.2 mg/ml), they were incubated 1 h at 37 °C and then centrifuged at 15,000 × g for 10 min at 4 °C. Expressed proteins formed inclusion bodies. The pellets were washed with TBS containing 0.5% Triton X-100 and 10 mM EDTA and then with H2O. The washed pellets were solubilized with 2 M NH4OH (20 ml) and then added to 25 mM MOPS buffer, pH 7.0, containing 2 mM glutathione, reduced form, 0.2 mM glutathione, oxidized form, 20 mM CaCl2, 0.5 M NaCl, and 0.02% NaN3 (20 ml). These solutions were then dialyzed against 25 mM MOPS buffer, pH 7.0, containing 20 mM CaCl2, 0.5 M NaCl, and 0.02% NaN3. Soluble recombinant mMGL1 and mMGL2 were purified by affinity chromatography on a column of galactose-Sepharose 4B, as described previously (24).

Solid Phase Binding Assays-- Absorption of the purified soluble recombinant mMGL1 or mMGL2 onto enzyme-linked immunosorbent assay plates (655061, Greiner) was carried out by adding 100 µl of solution (3 µg/ml in DPBS) to each well and incubating the plates for 18 h at 4 °C. After blocking of the wells using 3% bovine serum albumin (BSA) in DPBS for 2 h at room temperature, 150 µl solution of biotinylated soluble polyacrylamide with attached mono- or oligosaccharides (GlycoTech, Rockville, MD) or hybridoma culture supernatant, diluted into varying concentrations with DPBS containing 3% BSA, were added to each well. After incubation for 2 h at 4 °C (at room temperature for mAb reactions), the wells were washed three times with DPBS to remove unbound materials, and then 100 µl of HRP-conjugated streptavidin solution (1.25 µg/ml in DPBS) or HRP-conjugated goat anti-rat IgG (H + L) solution (0.375 µg/ml in DPBS) for rat mAbs was added to detect bound materials. After incubation for 1 h at room temperature, the wells were washed three times with DPBS. Subsequently, 100 µl of 1 mM 2, 2'-amino-bis(3-ethylbenzthiazoline-6-sulfonic acid) ammonium (ABTS) solution containing 0.34% H2O2 in 0.1 M sodium citrate buffer (pH 4.3) was added, and the absorbance was measured at 405 nm on a microplate reader (25).

To determine pH dependence of the binding of mMGL1 and mMGL2, the incubation conditions were modified as follows. After the blocking buffer was removed, the wells were washed three times with DPBS. Aliquots (50 µl) of biotinylated soluble polyacrylamide in 2× incubation buffer (274 mM NaCl, 26.8 mM KCl, 0.98 mM MgCl2, 1.810 mM CaCl2, 2% BSA) were mixed with equal volumes of 2× pH buffer (50 mM sodium acetate buffer at pH 4.5-6.0, 50 mM MES buffer at pH 6.0-7.0, 50 mM Tris-HCl buffer at pH 7.0-8.0) and transferred to each well. Incubation was performed at 4 °C for 1.5 h. The wells were emptied and washed three times with DPBST (DPBS containing 0.1% Tween 20) and 100 µl of HRP-conjugated streptavidin solution (Zymed Laboratories Inc., 1000 × in DPBS containing 1% BSA) was added and incubated for 1 h at 4 °C. The wells were emptied and washed three times with DPBST, and then 100 µl of ABTS solution containing 0.034% H2O2 (1 mM ABTS dissolved in 0.1 M sodium citrate buffer, pH 4.2) was added, and absorbance at 405 nm was determined.

Immunohistochemical Staining-- MGL-positive cells were immunohistochemically detected in the skin as described previously (19). In brief, skin samples freshly prepared from Mgl1-/- mice and their littermates were embedded in OCT compound (Miles, Elkhart, IN) and frozen in a liquid nitrogen bath. Cryostat sections (10 µm thick) were picked up on poly-L-lysine-coated slides and fixed in ice-cold acetone for 10 min. Nonspecific bindings were blocked using a blocking solution (2% normal mouse serum and 3% BSA in DPBS) for 10 min. The sections were treated with the first antibodies for 1 h and then treated with biotinylated mAb mouse anti-rat kappa  and lambda  (<FR><NU>1</NU><DE>50</DE></FR> dilution) for 30 min and finally treated with alkaline phosphatase-streptavidin (<FR><NU>1</NU><DE>100</DE></FR> dilution) for 30 min. The staining was visualized using Histomark Red, and the cell nucleus was counterstained in Mayer's hematoxylin after post-fixation using 2% glutaraldehyde in DPBS. The sections were observed under a light microscope (TMD-300, Nikon, Tokyo, Japan).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning of a Novel Macrophage C-type Lectin-- We found four clones (GenBankTM accession numbers AA511511, AA537107, AA671707, and AA498512) similar to mMGL (mMGL1, GenBankTM accession number S36676) and hMGL (HML-2, GenBankTM accession number D50532) in the data base of mouse expressed sequence tag. To obtain the full sequences of a novel C-type lectin, 5'- and 3'-RACE reactions were performed using mRNA from RAW264.7 cells as a template and with specific primers designed to match these expressed sequence tag clones. The full-length cDNA was prepared by RT-PCR of poly(A)+ RNA from RAW264.7 cells. The obtained full-length cDNA (GenBankTM accession number AY103461) encodes an open reading frame of 996 base pairs, predicting a protein of 332 amino acid residues (38,067 Da), which we subsequently termed mMGL2 (Fig. 1). The 3'-untranscription region has a sequence of long terminal repeat (LTR) of mouse early transposon (26, 27). The nucleotide sequence of mMGL2 has 79.0 and 54.9% identity with that of mMGL1 and hMGL (HML-2), respectively. The amino acid sequence of mMGL2 has 91.5 and 51.8% identity with that of mMGL1 and hMGL (HML-2), respectively. The neck domain is highly homologous to mMGL1 at 95.3%. Only five residues (Ile-87, Asn-108, Leu-144, Glu-166, and Thr-167) were different in the neck domain from Arg-78 to Gly-183. Amino acids within the CRD (corresponding to exons 8-10), particularly those corresponding to the last exon (exon 10), showed differences between mMGL1 and mMGL2. In the sequence of cytoplasmic domain (corresponding to exon 2), mMGL2 has a putative internalization signal (YXXPhi ) (28), which is also present in mMGL1, and an insertion of extra 14 amino acid residues. A consensus sequence for polyadenylation signal is present in nucleotides 1467-1472 followed by a poly(A) tail. There are two potential N-glycosylation sites (Fig. 1), both in mMGL1 and -2. 


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 1.   The nucleotide sequence of the mMGL2 cDNA. A, the nucleotide sequence of the mMGL2 cDNA and its deduced amino acid sequence. The putative transmembrane domain is underlined. The poly-A addition signal is underlined with a broken line. The potential N-glycosylation site is underlined with a wavy line. The putative internalization signal is boxed. B, amino acid sequences of mMGL1 and mMGL2. Asterisks mark the amino acid residues conserved in both lectins. Arrows indicate boundaries of exons.

Genomic Structure and Chromosome Location of mMGL2-- Screening of a 129/SvJ mouse genomic library led to the isolation of three clones. Two clones (termed 92b and 41b) were included in the Mgl (Mgl1) gene (GenBankTM accession number AF132744) (29), but the other clone (termed 41a) was included in the Mgl2 gene, confirmed by PCR using primers of mMGL2. The latter gene spans 7136 bp, consists of 10 exons, and is similar to Mgl (Mgl1) in genomic organization (Fig. 2A). The GenBankTM accession number of the Mgl2 gene is AY103462. The intron/exon boundaries were defined using DNA sequencing. All splice sites conform to the AG/GT rule (Table I). This clone contains 5'-upstream sequences. To identify the promoter sequences of the Mgl2 gene, transcription factor binding site consensus sequences were searched using the transcription factor data base (www.cbrc.jp/research/db/TFSEARCH.html). The promoter lacks a classical TATA box but contains several binding sites for other transcription factors, C/EBPbeta , CF1/, AML-1, c-Ets, PU.1, c-Rel, Oct-1, Lyf-1, AP-1, GATAs, and STATs. These features are almost identical to that of the 5'-flanking motifs of the Mgl1 gene. These are the sites found upstream of genes expressed preferentially by cells of monocyte/MØ lineages (Fig. 2C).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   Genomic structure of Mgl2 gene. As shown in A, the gene spans 7136 bp and consists of 10 exons and is a similar to Mgl1 in genomic organization. The untranslated regions are shown as closed boxes, and the coding regions are shown as hatched boxes. The initiation codon is within the second exon. B, the linkage of BAC clones. We identified the BAC clone RPCI-23-172M21, which encodes the Mgl2, Asgr1, and Asgr2 genes. RPCI-23-198E14 encodes Mgl2 and Mgl1. C, the promoter sequences of Mgl2 gene. Transcription factor binding site consensus sequences were searched using the transcription factor data base (www.cbrc.jp/ research/db/TFSEARCH.html).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Splice junction sequences, exon sizes, and estimated intron sizes of the mouse Mgl2 gene
Exon sequences are in capital letters; intron sequences are in lowercase letters.

We identified the BAC clone RPCI-23-172M21, which coded the Mgl2, Asgr1, and Asgr2 genes. The other clone RPCI-23-198E14 encodes the Mgl2 and Mgl1 genes. These BAC clones have been constructed from the genomic DNA of female C57BL/6J mice. Therefore, these four C-type lectin genes should be located within about 150 kb on mouse chromosome 11 (Fig. 2B).

Reactivity with Monoclonal Antibodies-- Previously, we have obtained mAbs specific for MGL1 using purified mMGL (likely to be a mixture of mMGL1 and mMGL2) and recombinant MGL1 as immunogens. Screening to obtain specific monoclonal antibodies was performed previously with recombinant mMGL1 (25). The antibodies are mAb LOM-4.7, mAb LOM-8.2, mAb LOM-8.7, all shown to have blocking activity, mAb LOM-11, shown to recognize the ligand-induced binding site, and a non-blocking mAb LOM-14 (25, 30). As shown in Fig. 3, mAb LOM-4.7, mAb LOM-8.2, mAb LOM-8.7, and mAb LOM-11 were shown to be specific for MGL1. LOM-14 bound to both MGL1 and MGL2 (Fig. 3). These results suggested that the most diverse region of these lectins was the ligand binding site.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Binding of mAbs to the recombinant mMGL1 and mMGL2. The binding of mAbs LOM-4.7, LOM-8.2, LOM-8.7, LOM-11, and LOM-14 to the immobilized recombinant mMGL1 (A) and mMGL2 (B) was measured according to mAb concentration. The binding of mAbs was detected using HRP-conjugated goat mAbs specific for rat IgG (H + L). Absorbance at 405 nm was measured on a microplate reader. The values represent means of triplicate determinations, and the error bars indicate S.D.

Distribution of mMGL2 mRNA in Tissue and Cells-- As a means of testing the expression profiles of this putative gene and mMgl1, RT-PCR analysis was performed on 10 mouse cell lines including L929 (fibroblast line), JLS-V9 (fibroblast-like bone marrow-derived cell line), EL4 (thymoma cell line), RLmale 1 (lymphoma cell line), YAC-1 (lymphoma cell line), BCL1-B20 (malignant B cells), P815 (mastocytoma cells), P388 (MØ-like lymphoid cell line), M1 (myeloblastic leukemia cells), and RAW264.7 (MØ-like cell line). The 644-bp bands indicating mMgl2 were found only in the cell lines P388 and RAW264.7 (Fig. 4A). These cell lines were also high expressers of mMgl1. To assess the expression patterns of mMgl1 and mMgl2 in vivo, RT-PCR analysis was conducted on RNA isolated from 13 different normal mouse tissues and embryos (Fig. 4B). These genes were expressed almost throughout the body, and the apparent relative intensities among different organs were similar between mMgl1 and mMgl2. To assess whether the expression levels of these genes correspond at single cell levels, TG-PEC were sorted for the binding of mAb LOM-8.7, an mAb specific for mMGL1, and then reacted with mAb LOM-14 reactive with both mMGL1 and mMGL2. As shown in Fig. 4C, cells strongly reactive with mAb LOM-8.7 were also reactive with mAb LOM-14. The ratios of expressed mRNAs corresponding to mMgl1 and mMgl2 shown by RT-PCR analysis were almost identical when unsorted mAb LOM-8.7-positive and mAb LOM-8.7-negative cells were compared. These results indicate that the mMgl1-positive cells also express the mMgl2 mRNA.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   RT-PCR analysis of mMGL1 and mMGL2 mRNA expression in cells and tissue. A, the cDNA was prepared from mouse cell lines (L929, JLS-V9, EL4, RLmale 1, YAC-1, BCL1-B20, P815, P388, RAW264.7, and M1). B, tissue cDNA (CLONTECH) was used after normalizing the relative amounts according to the levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA. C, TG-PEC were analyzed for the binding of mAbs LOM-14 and LOM-8.7. The cells highly or poorly reactive with mAb LOM-8.7 were separated and tested for mAb LOM-14 binding by flow cytometry. cDNA was prepared from the sorted cells, and RT-PCR analysis was performed. The PCR products were then separated on 1% agarose gels, stained with ethidium bromide, and visualized with the image analyzer. The ratios of band intensity of PCR products were measured. The panels represent a typical result of two separate experiments including cell fractionations. The results of these two separate experiments were almost identical.

mMGL2-positive Cells in Tissue Sections from Mgl1-/- Mice-- Frozen sections of skins from Mgl1-/- mice were stained with mAb LOM-8.7 and mAb LOM-14 (Fig. 5). The results revealed that Mgl1-/- mice expressed epitopes reactive with mAb LOM-14 at lower levels than Mgl1+/- mice but not with mAb LOM-8.7. These epitopes are likely to represent mMGL2. The subcellular localization of the mAb LOM-14 staining in Mgl1-/- mice did not appear to be distinct from that of mAb LOM-8.7 staining in Mgl1+/- mice.


View larger version (103K):
[in this window]
[in a new window]
 
Fig. 5.   Distribution of cells expressing mMGL1 and mMGL2 in skins. Frozen sections of skins from Mgl1-/- and Mgl1+/- mice were stained with mAb LOM-8.7 (specific for mMGL1) and mAb LOM-14 (cross-reactive between mMGL1 and mMGL2).

Carbohydrate Specificity of mMGL2-- A variety of biotin-labeled soluble polyacrylamides with mono- or oligosaccharides were applied to determine the carbohydrate specificity of mMGL1 and mMGL2 (Fig. 6). The carbohydrates tested are listed in the figure. The recombinant form of mMGL1 had the highest affinity with Lex residues among all carbohydrate-modified polyacrylamides tested. mMGL2 showed a very low affinity with LeX but showed the highest affinity with beta -linked GalNAc residues (Fig. 6). The bindings were inhibited with 5 mM EDTA (data not shown).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 6.   Carbohydrate specificity of recombinant mMGL1 and mMGL2. Binding of biotin-labeled soluble polyacrylamides containing mono- or oligosaccharides to immobilized recombinant mMGL1 (A and C) and mMGL2 (B and D). Amounts of bound polymers incubated at various concentrations were quantified using HRP-conjugated streptavidin. ABTS was used as a substrate, and absorbance at 405 nm was measured on a microplate reader. The panels represent a typical result of three separate determinations, which showed almost identical results. Each assay was performed in duplicate, and the mean value is shown.

pH-dependent Binding of Ligands to mMGL-- Enzyme-linked immunosorbent assays were performed under various pH conditions to determine the binding of soluble polyacrylamides with LeX residues or alpha -GalNAc residues to immobilized recombinant mMGL1 or mMGL2, respectively. Under a Ca2+ concentration similar to that found in extracellular fluids (0.905 mM), the binding decreased when pH was lowered from extracellular (pH 7.3) to endosomal (pH 5.4). The profiles of the pH-dependent binding were similar to that observed with intact hepatic asialoglycoprotein receptors (31). The pH value of a half-maximal ligand binding, designated as pHB, was 5.5 for MGL1 and 5.7 for MGL2 (Fig. 7).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 7.   Effects of pH on binding of recombinant mMGL1 and mMGL2. The binding of biotin-labeled soluble polyacrylamides (0.22 µg/ml Lex polyacrylamide or 0.67 µg/µl alpha -GalNAc polyacrylamide) to the immobilized recombinant mMGL1 (A) or mMGL2 (B) was determined under varied pH conditions. The assays were performed in the presence of 0.905 mM CaCl2. The values obtained in different buffers (25 mM sodium acetate buffer for pH 4.5-6.0, 25 mM MES buffer for pH 6.0-7.0, 25 mM Tris-HCl buffer for pH 7.0-8.0). The panels represent a typical result of two separate determinations, which showed almost identical results. The values represent means of duplicate determinations.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the present study, we found a novel MØ C-type lectin, mMGL2, and characterized its genomic structure, expression patterns, and carbohydrate specificity. The Mgl2 gene spans 7136 bp and consists of 10 exons, which is a similar genomic organization to that of the Mgl gene now renamed the Mgl1 gene. We reported that the Mgl1 gene linked to Trp53 and is located 1.8 ± 1.2 cM distal to D11Mit5 and 1.8 ± 1.2 cM proximal to Htt on mouse chromosome 11. Using a panel of DNA samples from two parental mice, C3H/HeJ-gld and (C3H/HeJ-gld × Mus spretus) F1 were digested with various restriction endonucleases and hybridized with a mMGL1 cDNA probe to determine the restriction fragment length polymorphism and to allow haplotype analyses (29). The hepatic asialoglycoprotein receptor genes (Asgr1 and Asgr2) were also known to be linked to Trp53 (32). We found BAC clones, which included these two C-type lectins. These results indicate that the highly homologous Mgl2 gene is linked within about 50 kb. Their homology and close genomic localization indicate that the original gene was duplicated recently. The human MGL (HML-2) gene was mapped in chromosome 17p and linked to ASGR1 and ASGR2. These results show that there is a cluster of type 2 C-type lectin genes on mouse chromosome 11 and on human 17p12-13. Likewise, the natural killer gene complex resided on mouse chromosome 6 and on human 12p (33, 34).

Although there was a high degree of sequence homology between mMGL1 and mMGL2, the sequences corresponding to cytoplasmic and CRD showed differences, suggesting that cytoplasmic tail associations and the carbohydrate recognitions are unique between mMGL1 and mMGL2. We showed that recombinant mMGL1 bound soluble polyacrylamides containing Lex oligosaccharides. mMGL2 had affinity with polyacrylamides containing alpha - or beta -GalNAc. It has been believed that C-type lectins contain a peptide segment that corresponds to the carbohydrate binding specificity within the CRD and that the sequence in Gal and GalNAc-binding lectins, such as ASGRs, is QPD. In contrast, the sequence in mannose-, fucose-, and GlcNAc specific lectins, such as serum mannose-binding proteins, was EPN. The sequence in both mMGL1 and -2 was QPD. However, it was obvious from our results that their fine specificities depended on other amino acids in the CRD (Figs. 6 and 8). Some of the amino acid residues important in the carbohydrate recognitions were conserved in mMGL1, mMGL2, hMGL, RHL-1 and -2, mASGR-1, and hASGR-1. Crystallographic determination of the structure of human ASGR-1 revealed amino acid residues important in sugar binding (35). Furthermore, rat hepatic asialoglycoprotein receptor was subjected to site-directed mutation. As a result, the pH dependence of ligand binding was shown to be mediated by His-256, Asp-266, and Arg-270 (36). Because these residues are also conserved in mMGL1 and -2, they should also be responsible for their pH dependence (Fig. 8). Amino acid residues responsible for the differential carbohydrate specificity between mMGL1 and -2 and other members of the C-type lectin family and the phylogeny of these lectins (Fig. 8) are yet to be elucidated.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 8.   Comparison of the amino acid sequences of the CRD of C-type lectins. A, multialignment of the CRD sequences of C-type lectins. B, evolutionary tree of sequence of CRD of C-type lectins. Abbreviations used in this figure are: MHL, mouse hepatic lectin; rKCR, rat Kupffer cell receptor; mKCR, mouse Kupffer cell receptor.

There is a possibility that mMGL1 and -2 form heterooligomers. These lectins are known to form trimeric structures through the interactions of the neck domain in a similar manner to that of ASGRs. ASGRs are abundantly expressed on the sinusoidal surface of hepatic parenchymal cells (37, 38). Its primary role is the removal and degradation of desialylated glycoproteins from circulation. High affinity binding requires the receptor to be assembled as a heterooligomer consisting of two highly homologous subunits, termed hepatic lectin 1 and 2 (39). Experiments with recombinant rat hepatic lectins suggested that the binding properties of the major subunit (RHL-1) and the minor subunit (RHL-2/-3) were optimized for different ligands (40). In the case of mMGL1 and -2, the recombinant form corresponding to each one showed affinity with different carbohydrates, indicating that heterooligomer formation was not required for their carbohydrate recognition. However, these lectins were likely to be expressed on the same cells at the single cell level and cooperatively functioned to recognize and uptake extracellular molecules.

mMGL1-positive cells are abundant in connective tissues throughout the body (19). mMGL1 was shown to be expressed on the surfaces of bone marrow-derived immature dendritic cells (21). hMGL is also shown to be expressed on monocyte-derived immature dendritic cells and monocyte-derived immature MØs in humans (41). We have shown that mMGL1-positive cells migrate from dermis to regional lymph nodes during the sensitization phase of contact hypersensitivity (42). The migration was initiated by cytokine-mediated release of mMGL1-positive cells from dermis (42-44). The cells homed to the boundary of the T-cell area in the regional lymph nodes, and the prevention of migration seemed to interfere with sensitization. Involvement of coordinated functions of mMGL1 and -2 in such pathogenic processes should be the most important subject of future investigations.

    FOOTNOTES

* This work was supported by grants-in-aid from the Ministry of Education, Science, Sports and Culture of Japan (09254101, 11557180, 11672162, and 12307054), from the Research Association for Biotechnology, Special Coordination Funds for Promoting Science and Technology of the Ministry of Education, Culture, Sports, Science and Technology, and from the Program for Promotion of Basic Research Activities for Innovative Biosciences.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the DDBJ/GenBankTM/EBI Data Bank with accession number(s) AY103461, AY103462.

Dagger Present address: Dept. of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.

To whom correspondence should be addressed. Tel.: 813-5841-4870; Fax: 813-5841-4879; E-mail: irimura@mol.f.u-tokyo.ac.jp.

Published, JBC Papers in Press, May 16, 2002, DOI 10.1074/jbc.M203774200

    ABBREVIATIONS

The abbreviations used are: MØ, macrophage; ABTS, 2,2'-amino-bis(3-ethylbenzthiazoline-6-sulfonic acid); ASGR, hepatic asialoglycoprotein receptor; BAC, bacterial artificial chromosome; BSA, bovine serum albumin; CRD, carbohydrate-recognition domain; DPBS, Dulbecco's phosphate-buffered saline; HRP, horseradish peroxidase; MGL, macrophage galactose-type C-type lectin; RHL, rat hepatic lectin; RT, reverse transcriptase; TG-PEC, thioglycollate-induced peritoneal cells; RACE, rapid amplification of cDNA ends; STAT, signal transducers and activators of transcription; mAb, monoclonal antibody; MES, 4-morpholineethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid; h, human; m, mouse; r, rat.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Lewis, C., and McGee, J. O. D. (1992) The Macrophage: The Natural Immune System , pp. 1-413, IRL Press at Oxford University Press, Oxford
2. Feizi, T. (2000) Immunol. Rev. 173, 79-88[CrossRef][Medline] [Order article via Infotrieve]
3. McKnight, A. J., and Gordon, S. (1998) Adv. Immunol. 68, 271-314[Medline] [Order article via Infotrieve]
4. Linehan, S. A., Martinez-Pomares, L., and Gordon, S. (2000) Microbes Infect. 2, 279-288[CrossRef][Medline] [Order article via Infotrieve]
5. Weis, W. I., Taylor, M. E., and Drickamer, K. (1998) Immunol. Rev. 163, 19-34[CrossRef][Medline] [Order article via Infotrieve]
6. Stahl, P. D., and Ezekowitz, R. A. (1998) Curr. Opin. Immunol. 10, 50-55[CrossRef][Medline] [Order article via Infotrieve]
7. Liu, Y., Chirino, A. J., Misulovin, Z., Leteux, C., Feizi, T., Nussenzweig, M. C., and Bjorkman, P. J. (2000) J. Exp. Med. 191, 1105-1116[Abstract/Free Full Text]
8. Leteux, C., Chai, W., Loveless, R. W., Yuen, C. T., Uhlin-Hansen, L., Combarnous, Y., Jankovic, M., Maric, S. C., Misulovin, Z., Nussenzweig, M. C., and Ten, F. (2000) J. Exp. Med. 191, 1117-1126[Abstract/Free Full Text]
9. Ozaki, K., Ii, M., Itoh, N., and Kawasaki, T. (1992) J. Biol. Chem. 267, 9229-9235[Abstract/Free Full Text]
10. Kawakami, K., Yamamoto, K., Toyoshima, S., Osawa, T., and Irimura, T. (1994) Jpn. J. Cancer Res. 85, 744-749[CrossRef][Medline] [Order article via Infotrieve]
11. Valladeau, J., Duvert-Frances, V., Pin, J. J., Kleijmeer, M. J., Ait-Yahia, S., Ravel, O., Vincent, C., Vega, F., Jr., Helms, A., Gorman, D., Zurawski, S. M., Zurawski, G., Ford, J., and Saeland, S. (2001) J. Immunol. 167, 5767-5774[Abstract/Free Full Text]
12. Yamamoto, K., Ishida, C., Shinohara, Y., Hasegawa, Y., Konami, Y., Osawa, T., and Irimura, T. (1994) Biochemistry 33, 8159-8166[CrossRef][Medline] [Order article via Infotrieve]
13. Suzuki, N., Yamamoto, K., Toyoshima, S., Osawa, T., and Irimura, T. (1996) J. Immunol. 156, 128-135[Abstract]
14. Iida, S., Yamamoto, K., and Irimura, T. (1999) J. Biol. Chem. 274, 10697-10705[Abstract/Free Full Text]
15. Sakamaki, T., Imai, Y., and Irimura, T. (1995) J. Leukocyte Biol. 57, 407-414[Abstract]
16. Ichii, S., Imai, Y., and Irimura, T. (1997) J. Leukocyte Biol. 62, 761-770[Abstract]
17. Ichii, S., Imai, Y., and Irimura, T. (2000) Cancer Immunol. Immunother. 49, 1-9[CrossRef][Medline] [Order article via Infotrieve]
18. Imai, Y., Akimoto, Y., Mizuochi, S., Kimura, T., Hirano, H., and Irimura, T. (1995) Immunology 86, 591-598[Medline] [Order article via Infotrieve]
19. Mizuochi, S., Akimoto, Y., Imai, Y., Hirano, H., and Irimura, T. (1997) Glycobiology 7, 137-146[Abstract/Free Full Text]
20. Mizuochi, S., Akimoto, Y., Imai, Y., Hirano, H., and Irimura, T. (1998) Glycoconj. J. 15, 397-404[CrossRef][Medline] [Order article via Infotrieve]
21. Denda-Nagai, K., Kubota, N., Tsuiji, M., Kamata, M., and Irimura, T. (2002) Glycobiology 12, 443-450[Abstract/Free Full Text]
22. Higashi, N., Fujioka, K., Denda-Nagai, K., Hashimoto, S., Nagai, S., Sato, T., Fujita, Y., Morikawa, A., Tsuiji, M., Miyata-Takeuchi, M., Sano, Y., Suzuki, N., Yamamoto, K., Matsushima, K., and Irimura, T. (2002) J. Biol. Chem. 277, 20686-20693[Abstract/Free Full Text]
23. Onami, T. M, Lin, M.-Y., Page, D. M., Reynolds, S. A., Katayama, C. D., Marth, J. D., Irimura, T., Varki, A., Varki, N., and Hedrick, S. M. (2002) Mol. Cell. Biol. 22, 5173-5181[Abstract/Free Full Text]
24. Sato, M., Kawakami, K., Osawa, T., and Toyoshima, S. (1992) J Biochem. (Tokyo) 111, 331-336[Abstract/Free Full Text]
25. Kimura, T., Imai, Y., and Irimura, T. (1995) J. Biol. Chem. 270, 16056-16062[Abstract/Free Full Text]
26. Tanaka, I., and Ishihara, H. (2001) Virology 280, 107-114[CrossRef][Medline] [Order article via Infotrieve]
27. Mager, D. L., and Freeman, J. D. (2000) J. Virol. 74, 7221-7229[Abstract/Free Full Text]
28. Trowbridge, I. S. (1991) Curr. Opin. Cell Biol. 3, 634-641[CrossRef][Medline] [Order article via Infotrieve]
29. Tsuiji, M., Fujimori, M., Seldin, M. F., Taketo, M. M., and Irimura, T. (1999) Immunogenetics 50, 67-70[CrossRef][Medline] [Order article via Infotrieve]
30. Kimura, T., Hosoi, T., Yamamoto, K., Suzuki, N., Imai, Y., and Irimura, T. (2000) Mol. Immunol. 37, 151-160[CrossRef][Medline] [Order article via Infotrieve]
31. Hudgin, R. L., Pricer, W. E., Jr., Ashwell, G., Stockert, R. J., and Morell, A. G. (1974) J Biol. Chem 249, 5536-5543[Abstract/Free Full Text]
32. Blackburn, C. C., Griffith, J., and Morahan, G. (1995) Genomics 26, 308-317[CrossRef][Medline] [Order article via Infotrieve]
33. Yokoyama, W. M., and Seaman, W. E. (1993) Annu. Rev. Immunol. 11, 613-635[Medline] [Order article via Infotrieve]
34. Brown, M. G., Fulmek, S., Matsumoto, K., Cho, R., Lyons, P. A., Levy, E. R., Scalzo, A. A., and Yokoyama, W. M. (1997) Genomics 42, 16-25[CrossRef][Medline] [Order article via Infotrieve]
35. Meier, M., Bider, M. D., Malashkevich, V. N., Spiess, M., and Burkhard, P. (2000) J. Mol. Biol. 300, 857-865[CrossRef][Medline] [Order article via Infotrieve]
36. Wragg, S., and Drickamer, K. (1999) J. Biol. Chem. 274, 35400-35406[Abstract/Free Full Text]
37. Collins, J. C., Stockert, R. J., and Morell, A. G. (1984) Hepatology 4, 80-83[Medline] [Order article via Infotrieve]
38. Braun, J. R., Willnow, T. E., Ishibashi, S., Ashwell, G., and Herz, J. (1996) J. Biol. Chem. 271, 21160-21166[Abstract/Free Full Text]
39. Bider, M. D., and Spiess, M. (1998) FEBS Lett. 434, 37-41[CrossRef][Medline] [Order article via Infotrieve]
40. Ruiz, N. I., and Drickamer, K. (1996) Glycobiology 6, 551-559[Abstract/Free Full Text]
41. Higashi, N., Morikawa, A, Fujioka, K, Fujita, Y., Sano, Y., Miyata-Takeuchi, M., Suzuki, N., and Irimura, T. (2002) Int. Immunol. 14, 545-554[Abstract/Free Full Text]
42. Sato, K., Imai, Y., and Irimura, T. (1998) J. Immunol. 161, 6835-6844[Abstract/Free Full Text]
43. Chun, K. H., Imai, Y., Higashi, N., and Irimura, T. (2000) J. Leukocyte Biol. 68, 471-478[Abstract/Free Full Text]
44. Chun, K. H., Imai, Y., Higashi, N., and Irimura, T. (2000) Int. Immunol. 12, 1695-1703[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
S. J. van Vliet, L. C. Paessens, V. C. M. Broks-van den Berg, T. B. H. Geijtenbeek, and Y. van Kooyk
The C-Type Lectin Macrophage Galactose-Type Lectin Impedes Migration of Immature APCs
J. Immunol., September 1, 2008; 181(5): 3148 - 3155.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
Y. Sano, K. Usami, R. Izawa, K. Denda-Nagai, N. Higashi, T. Kimura, N. Suzuki, and T. Irimura
Properties of Blocking and Non-blocking Monoclonal Antibodies Specific for Human Macrophage Galactose-type C-type Lectin (MGL/ClecSF10A/CD301)
J. Biochem., January 1, 2007; 141(1): 127 - 136.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. Dupasquier, P. Stoitzner, H. Wan, D. Cerqueira, A. van Oudenaren, J. S. A. Voerman, K. Denda-Nagai, T. Irimura, G. Raes, N. Romani, et al.
The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling
J. Leukoc. Biol., October 1, 2006; 80(4): 838 - 849.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
P. J. Coombs, M. E. Taylor, and K. Drickamer
Two categories of mammalian galactose-binding receptors distinguished by glycan array profiling
Glycobiology, August 1, 2006; 16(8): 1C - 7C.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
E. M. Comelli, S. R. Head, T. Gilmartin, T. Whisenant, S. M. Haslam, S. J. North, N.-K. Wong, T. Kudo, H. Narimatsu, J. D. Esko, et al.
A focused microarray approach to functional glycomics: transcriptional regulation of the glycome
Glycobiology, February 1, 2006; 16(2): 117 - 131.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
H. Yuita, M. Tsuiji, Y. Tajika, Y. Matsumoto, K. Hirano, N. Suzuki, and T. Irimura
Retardation of removal of radiation-induced apoptotic cells in developing neural tubes in macrophage galactose-type C-type lectin-1-deficient mouse embryos
Glycobiology, December 1, 2005; 15(12): 1368 - 1375.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Sato, Y. Imai, N. Higashi, Y. Kumamoto, T. M. Onami, S. M. Hedrick, and T. Irimura
Lack of antigen-specific tissue remodeling in mice deficient in the macrophage galactose-type calcium-type lectin 1/CD301a
Blood, July 1, 2005; 106(1): 207 - 215.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S. J. van Vliet, E. van Liempt, E. Saeland, C. A. Aarnoudse, B. Appelmelk, T. Irimura, T. B. H. Geijtenbeek, O. Blixt, R. Alvarez, I. van Die, et al.
Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells
Int. Immunol., May 1, 2005; 17(5): 661 - 669.
[Abstract] [Full Text] [PDF]